Skip to main content

Artificial Intelligence Could Be About To Replace Your Doctor

FN Media Group Presents Market Commentary


London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global healthcare industry, America is definitely not first. Americans are fed up, and a digital revolution that goes way beyond telemedicine is the only thing that will restore control.  Mentioned in today’s commentary includes:   Sage Therapeutics, Inc. (NASDAQ: SAGE), Cassava Sciences, Inc. (NASDAQ: SAVA), COMPASS Pathways plc (NASDAQ: CMPS), Neuronetics, Inc. (NASDAQ: STIM), Acadia Healthcare Company, Inc. (NASDAQ: ACHC).


Fixing it is a highly disruptive, multi-trillion-dollar opportunity. Telemedicine, or ‘Telehealth’, will soar from $42 billion in 2018 to $400 billion in 2026. Healthcare IT alone will be worth $390 billion by 2024.  But the biggest disruptor of them all may be medical apps. And the advantage just might go to a Canadian company with perhaps the most sophisticated AI the healthcare sector has ever seen …


Because it was developed by, and trained by, a huge team of doctors and medical experts from all over the world. Now, it’s about to launch in North America. And plans to then go global. City by city.


The company is International Inc. (TRUE; TREIF) and the world has never seen anything like global library of medicine, nor CARA, the new doctor-developed AI that could be set to revolutionize the $11 trillion healthcare industry


CARA is personalized in every way. CARA, Treatment’s Digital Assistant assesses symptoms based on your actual information; CARA helps you to diagnose health problems, makes recommendations, tracks and monitors your symptoms and follows up with your healthcare every step of the way. From cradle to grave, CARA helps you and your entire family (including caregivers) manage healthcare.  The technology is 100% proprietary and it’s ready to win over a massive consumer base that is begging for a healthcare revolution.


AI Healthcare Is Here


Medical apps are tapped to be the fastest-growing IT healthcare segment, with consumers starving for better services that they can actually control and understand. We’re just at the beginning of a complete revolution in the healthcare industry, and is the first to truly attempt to empower the consumer with AI that thinks like a doctor because it was trained by real doctors over the past six years. The team behind it has a near perfect track record in building and scaling IT infrastructure, particularly in the healthcare sector, with major rewards for investors.


For the past 6 years, a team of over 40 global world-class medical experts have been working to build the AI infrastructure for CARA and International Inc. The AI is already so sophisticated it’s been licensed by the University of Minnesota Medical School to teach and test medical students.


The Rush For Healthcare Solutions Is Heating Up


UK-based Babylon Health, a telehealth startup, is set to go public in the U.S. via a $4.2-billion SPAC deal.  Big money should be looking for better deals than this, though. Deals that prioritize and emphasize artificial intelligence.


That’s what makes Babylon less attractive than it could be, says’s Dr. Keven Peterson. “Babylon has struggled to provide an effective [AI powered] clinical decision support product. Their revenues are based on their clinical telemedicine, which uses the weakness of their app to draw people into the telemedicine interaction,” Peterson said, commenting on the $4.2-billion SPAC deal. International offers digital capabilities powered by AI that are stronger than anything thrown at the market to date.


Medical apps powered by AI are poised to explode precisely because the AI brings everything together, intelligently. Americans are desperate for healthcare clarity; gives it to them. Googling symptoms does not.


CARA isn’t a game of googling symptoms and coming up with the most-searched piece of potential, anxiety-causing misinformation. CARA uses your medical records and the power of sophisticated AI trained by doctors to assess your symptoms and get you the care that you need, seamlessly.


All of this makes the underlying, 100% owned proprietary IP something that should have investor interest piqued. Keep this name on your radar as International (TRUE; TREIF) plans to launch it’s ground-breaking APP – ‘CARA’ – powered by the most comprehensive AI in the industry, before the end of this year.


 The Healthcare Industry Is Ripe For Disruption


Sage Therapeutics (SAGE)  is an incredible example of a company using its immense resources and knowhow to tackle the growing health crisis in the United States and abroad. With a focus on exciting new ways to treat mental health disorders, the company released the only FDA-approved treatment for post-partum depression.


Dr. Jeffrey Cohen founded Sage Therapeutics in 2003 with a mission to discover and develop life-saving medicines for rare diseases. The company has gone on create treatments that have been approved all around the world, including Pompe disease, Sanfilippo syndrome type A (a form of although largely affecting children), Fabry disease as well Gaucher Disease which can be hereditary or caused by environmental factors such food intolerance issues like gluten sensitivity among others.


Cassava Sciences (SAVA)  is a clinical-stage biopharmaceutical company focused on neurosciences. They are committed to advancing neuroscience research and developing novel therapies for patients with brain disorders. The founders of Cassava Sciences have an extensive background in both biotechnology and the pharmaceutical industry, which gives them the expertise needed to lead the company into its next phase of growth.


Cassava Sciences was founded by two scientists who worked together at Pfizer Pharmaceuticals for over 20 years before they left the company in 2015 to start their own biotech startup, one that would focus on solving some of medicine’s most difficult problems. Since then, they’ve recruited a team of likeminded individuals with deep scientific experience, as well as key partnerships with leading universities around the world.


COMPASS Pathways plc (CMPS) COMP360 solution has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. COMPASS’ meticulous approach to psilocybin treatments is important because, while legalization may look imminent, there’s still a long road ahead for this relatively new medicine.


CEO George Goldsmith explained. “There simply isn’t yet enough evidence of safety and efficacy of psilocybin therapy, which is why we’re doing our trials,” adding “the review and approval to regulatory agencies is really the best way ensure the safety, efficacy and quality of any medicine or therapy.”


Neuronetics, Inc. (STIM) is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The company’s first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.


Neuronetics’ TouchStar protocol is a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD). Greg Harper, Vice President of Product Development and Operations at Neuronetics, explained, The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location.”


Acadia Healthcare Company, Inc. (ACHC)  is a company that provides healthcare services in the United States. The company offers medical management for post-acute care and rehabilitation needs of patients after they have been discharged from hospital settings or skilled nursing facilities.


Acadia Healthcare also offers a wide range of behavioral health and addiction services to its patients through the use of evidence-based treatment methods.  The company is primarily focused on providing a continuum of care for individuals in need with mental health and substance abuse related issues by developing personalized treatment plans that are designed to meet the specific needs of each individual they serve, while also providing support for family members or friends who may be involved in their recovery process.


By. William Thomas




This article is a paid advertisement. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by International Inc. (“” or “Company”) to conduct investor awareness advertising and marketing. paid the Publisher four hundred and fifty thousand US dollars to produce and disseminate four articles profiling the Company. This compensation should be viewed as a major conflict with our ability to be unbiased.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.


SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.


FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the companies’ products, the prospects for success of the Company’s to be launched health and wellness app – “CARA”, the reported scheduled release of CARA, the ability to acquire customers for CARA, and the projected growth and profit margins of the Company’s core product offerings.  Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the launch of CARA, competition, market saturation, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.


INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.


TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


INTELLECTUAL PROPERTY. is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.


DISCLAIMER: is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein.  The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.


Contact Information:

Media Contact e-mail:  U.S. Phone: +1(954)345-0611



The post Artificial Intelligence Could Be About To Replace Your Doctor appeared first on Financial News Media.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.